Finanzen von Beam Therapeutics Inc. (BEAM)BEAMBeam Therapeutics Inc.

Evaluating the bottom line, Beam Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25827.14%, while the net margin is -25036.33%. These profitability ratios, combined with a Return on Equity (ROE) of -8.18%, provide a clear picture of how effectively BEAM converts its operational activities into shareholder value.

In the context of the broader market, BEAM competes directly with industry leaders such as MESO and MBX. With a market capitalization of $2.44B, it holds a significant position in the sector. When comparing efficiency, BEAM's gross margin of 100.00% stands against MESO's 85.19% and MBX's N/A. Such benchmarking helps identify whether Beam Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Beam's gross margin remains strong at 100%, indicating no cost of goods sold, but it has reported significant net losses, with a net income of -122678000 USD in Q2 2026. The forward P/E is currently 0, reflecting a lack of earnings expectations in the near term, which is common in biotech firms at this stage of development.